Review



calpeptin (calp, 400 mu/µl, dmf)  (Cytoskeleton Inc)


Bioz Verified Symbol Cytoskeleton Inc is a verified supplier
Bioz Manufacturer Symbol Cytoskeleton Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cytoskeleton Inc calpeptin (calp, 400 mu/µl, dmf)
    A. Estimation of GTP-bound ‘active’ rhoA in uterine myocytes treated with Calp or vehicle (DMF) for 15 min (n = 2). RhoA content was quantified relative to α-actin loading control, and used to correct rhoA activity data. Error bars represent standard deviations. B. Quantification of pRLC and ppRLC in uterine myocytes treated with Calp and with increasing concentrations of a cell-permeable rhoA inhibitor (C3 transferase) by ICW (n = 4). * and ** indicate significant differences from vehicle or Calp alone (second histogram), respectively. Calp <t>(calpeptin);</t> rhoA activator (0.5 mU/mL). p<0.05 in all cases as determined by one-way ANOVA followed by Tukey test.
    Calpeptin (Calp, 400 Mu/µl, Dmf), supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/calpeptin+calp/calpeptin/pmc03111472-210-0-21
    Average 90 stars, based on 1 article reviews
    calpeptin (calp, 400 mu/µl, dmf) - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Phos-Tag-Based Analysis of Myosin Regulatory Light Chain Phosphorylation in Human Uterine Myocytes"

    Article Title: Phos-Tag-Based Analysis of Myosin Regulatory Light Chain Phosphorylation in Human Uterine Myocytes

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0020903

    A. Estimation of GTP-bound ‘active’ rhoA in uterine myocytes treated with Calp or vehicle (DMF) for 15 min (n = 2). RhoA content was quantified relative to α-actin loading control, and used to correct rhoA activity data. Error bars represent standard deviations. B. Quantification of pRLC and ppRLC in uterine myocytes treated with Calp and with increasing concentrations of a cell-permeable rhoA inhibitor (C3 transferase) by ICW (n = 4). * and ** indicate significant differences from vehicle or Calp alone (second histogram), respectively. Calp (calpeptin); rhoA activator (0.5 mU/mL). p<0.05 in all cases as determined by one-way ANOVA followed by Tukey test.
    Figure Legend Snippet: A. Estimation of GTP-bound ‘active’ rhoA in uterine myocytes treated with Calp or vehicle (DMF) for 15 min (n = 2). RhoA content was quantified relative to α-actin loading control, and used to correct rhoA activity data. Error bars represent standard deviations. B. Quantification of pRLC and ppRLC in uterine myocytes treated with Calp and with increasing concentrations of a cell-permeable rhoA inhibitor (C3 transferase) by ICW (n = 4). * and ** indicate significant differences from vehicle or Calp alone (second histogram), respectively. Calp (calpeptin); rhoA activator (0.5 mU/mL). p<0.05 in all cases as determined by one-way ANOVA followed by Tukey test.

    Techniques Used: Activity Assay

    Panels A-D correspond to WB data derived using an Ab directed toward the C-terminus of RLC. A. Representative WBs demonstrating RLC phospho-states separated by Mn 2+ -phos-tag SDS-PAGE. Uterine myocytes were lysed and total protein was harvested after the following treatments: untreated, or treated with g-H, Calp, OT, or with their corresponding vehicles. B. Quantification of bands identified in panel A (untreated; n = 12, g-H; n = 5, Calp; n = 8, OT; n = 7). The signals derived from 0pRLC T , 1pRLC T , and 2pRLC T are expressed as the proportion of their sum total within each lane. C. Absolute magnitude of the difference in each phospho-state caused by the treatments in comparison to the corresponding vehicle (‘+’ indicates enhancement relative to vehicle, ‘−’ indicates diminution relative to vehicle). D. Vehicle-corrected distribution data obtained by combining the data in panel C to the untreated group distribution. g-H (glycyl-H-1152); ROK inhibitor (1 µM). Calp (calpeptin); rhoA activator (0.5 mU/mL). OT; oxytocin (100 nM). All data are shown as means ± SEMs. The corresponding numerical data are compiled in .
    Figure Legend Snippet: Panels A-D correspond to WB data derived using an Ab directed toward the C-terminus of RLC. A. Representative WBs demonstrating RLC phospho-states separated by Mn 2+ -phos-tag SDS-PAGE. Uterine myocytes were lysed and total protein was harvested after the following treatments: untreated, or treated with g-H, Calp, OT, or with their corresponding vehicles. B. Quantification of bands identified in panel A (untreated; n = 12, g-H; n = 5, Calp; n = 8, OT; n = 7). The signals derived from 0pRLC T , 1pRLC T , and 2pRLC T are expressed as the proportion of their sum total within each lane. C. Absolute magnitude of the difference in each phospho-state caused by the treatments in comparison to the corresponding vehicle (‘+’ indicates enhancement relative to vehicle, ‘−’ indicates diminution relative to vehicle). D. Vehicle-corrected distribution data obtained by combining the data in panel C to the untreated group distribution. g-H (glycyl-H-1152); ROK inhibitor (1 µM). Calp (calpeptin); rhoA activator (0.5 mU/mL). OT; oxytocin (100 nM). All data are shown as means ± SEMs. The corresponding numerical data are compiled in .

    Techniques Used: Derivative Assay, SDS Page

    Related Articles

    other:

    Article Title: Evolving cross-talk in the neutrophil polarity network
    Article Snippet: The concentrations for each drug were as follows: 50nM for latrunculin A (LatA) (Sigma, L5163), 0.4μM for jasplakinolide (Jas) (Sigma, C5231), 9μM for nocodazole (Noco) (Sigma, M1404), 5μM for taxol (Taxol) (Sigma, T1912), 25μM for Y27632 (Y27632) (Sigma, Y0503) and 2μg/μl for calpeptin (Calp) (Cytoskeleton, CN01-A) ( Figure S1C ).



    Similar Products

    calpeptin (calp, 400 mu/µl, dmf)  (Cytoskeleton Inc)
    90
    Cytoskeleton Inc calpeptin (calp, 400 mu/µl, dmf)
    A. Estimation of GTP-bound ‘active’ rhoA in uterine myocytes treated with Calp or vehicle (DMF) for 15 min (n = 2). RhoA content was quantified relative to α-actin loading control, and used to correct rhoA activity data. Error bars represent standard deviations. B. Quantification of pRLC and ppRLC in uterine myocytes treated with Calp and with increasing concentrations of a cell-permeable rhoA inhibitor (C3 transferase) by ICW (n = 4). * and ** indicate significant differences from vehicle or Calp alone (second histogram), respectively. Calp <t>(calpeptin);</t> rhoA activator (0.5 mU/mL). p<0.05 in all cases as determined by one-way ANOVA followed by Tukey test.
    Calpeptin (Calp, 400 Mu/µl, Dmf), supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/calpeptin+calp/calpeptin/pmc03111472-210-0-21
    Average 90 stars, based on 1 article reviews
    calpeptin (calp, 400 mu/µl, dmf) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    n-benzyloxycarbonyl-leucyl-l-norleucinal (calpeptin, calp  (Millipore)
    90
    Millipore n-benzyloxycarbonyl-leucyl-l-norleucinal (calpeptin, calp
    A. Estimation of GTP-bound ‘active’ rhoA in uterine myocytes treated with Calp or vehicle (DMF) for 15 min (n = 2). RhoA content was quantified relative to α-actin loading control, and used to correct rhoA activity data. Error bars represent standard deviations. B. Quantification of pRLC and ppRLC in uterine myocytes treated with Calp and with increasing concentrations of a cell-permeable rhoA inhibitor (C3 transferase) by ICW (n = 4). * and ** indicate significant differences from vehicle or Calp alone (second histogram), respectively. Calp <t>(calpeptin);</t> rhoA activator (0.5 mU/mL). p<0.05 in all cases as determined by one-way ANOVA followed by Tukey test.
    N Benzyloxycarbonyl Leucyl L Norleucinal (Calpeptin, Calp, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/calpeptin+calp/benzyloxycarbonylleucyl+norleucinal+calpeptin/pm23495712-53-0-14
    Average 90 stars, based on 1 article reviews
    n-benzyloxycarbonyl-leucyl-l-norleucinal (calpeptin, calp - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    calpeptin calp  (Cytoskeleton Inc)
    95
    Cytoskeleton Inc calpeptin calp
    A. Estimation of GTP-bound ‘active’ rhoA in uterine myocytes treated with Calp or vehicle (DMF) for 15 min (n = 2). RhoA content was quantified relative to α-actin loading control, and used to correct rhoA activity data. Error bars represent standard deviations. B. Quantification of pRLC and ppRLC in uterine myocytes treated with Calp and with increasing concentrations of a cell-permeable rhoA inhibitor (C3 transferase) by ICW (n = 4). * and ** indicate significant differences from vehicle or Calp alone (second histogram), respectively. Calp <t>(calpeptin);</t> rhoA activator (0.5 mU/mL). p<0.05 in all cases as determined by one-way ANOVA followed by Tukey test.
    Calpeptin Calp, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/calpeptin+calp/Rho+Activator/pmc03614011-273-42-44
    Average 95 stars, based on 1 article reviews
    calpeptin calp - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    calpain inhibitor calpeptin calp  (Millipore)
    90
    Millipore calpain inhibitor calpeptin calp
    A. Estimation of GTP-bound ‘active’ rhoA in uterine myocytes treated with Calp or vehicle (DMF) for 15 min (n = 2). RhoA content was quantified relative to α-actin loading control, and used to correct rhoA activity data. Error bars represent standard deviations. B. Quantification of pRLC and ppRLC in uterine myocytes treated with Calp and with increasing concentrations of a cell-permeable rhoA inhibitor (C3 transferase) by ICW (n = 4). * and ** indicate significant differences from vehicle or Calp alone (second histogram), respectively. Calp <t>(calpeptin);</t> rhoA activator (0.5 mU/mL). p<0.05 in all cases as determined by one-way ANOVA followed by Tukey test.
    Calpain Inhibitor Calpeptin Calp, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/calpeptin+calp/calpain+inhibitor+calpeptin+calp/pmc02265381-65-7-11
    Average 90 stars, based on 1 article reviews
    calpain inhibitor calpeptin calp - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    calpeptin (calp)  (Millipore)
    90
    Millipore calpeptin (calp)
    A. Estimation of GTP-bound ‘active’ rhoA in uterine myocytes treated with Calp or vehicle (DMF) for 15 min (n = 2). RhoA content was quantified relative to α-actin loading control, and used to correct rhoA activity data. Error bars represent standard deviations. B. Quantification of pRLC and ppRLC in uterine myocytes treated with Calp and with increasing concentrations of a cell-permeable rhoA inhibitor (C3 transferase) by ICW (n = 4). * and ** indicate significant differences from vehicle or Calp alone (second histogram), respectively. Calp <t>(calpeptin);</t> rhoA activator (0.5 mU/mL). p<0.05 in all cases as determined by one-way ANOVA followed by Tukey test.
    Calpeptin (Calp), supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/calpeptin+calp/calpeptin++cal+p+/10__3233_slash_ch___2008___1101-45-0-7
    Average 90 stars, based on 1 article reviews
    calpeptin (calp) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    A. Estimation of GTP-bound ‘active’ rhoA in uterine myocytes treated with Calp or vehicle (DMF) for 15 min (n = 2). RhoA content was quantified relative to α-actin loading control, and used to correct rhoA activity data. Error bars represent standard deviations. B. Quantification of pRLC and ppRLC in uterine myocytes treated with Calp and with increasing concentrations of a cell-permeable rhoA inhibitor (C3 transferase) by ICW (n = 4). * and ** indicate significant differences from vehicle or Calp alone (second histogram), respectively. Calp (calpeptin); rhoA activator (0.5 mU/mL). p<0.05 in all cases as determined by one-way ANOVA followed by Tukey test.

    Journal: PLoS ONE

    Article Title: Phos-Tag-Based Analysis of Myosin Regulatory Light Chain Phosphorylation in Human Uterine Myocytes

    doi: 10.1371/journal.pone.0020903

    Figure Lengend Snippet: A. Estimation of GTP-bound ‘active’ rhoA in uterine myocytes treated with Calp or vehicle (DMF) for 15 min (n = 2). RhoA content was quantified relative to α-actin loading control, and used to correct rhoA activity data. Error bars represent standard deviations. B. Quantification of pRLC and ppRLC in uterine myocytes treated with Calp and with increasing concentrations of a cell-permeable rhoA inhibitor (C3 transferase) by ICW (n = 4). * and ** indicate significant differences from vehicle or Calp alone (second histogram), respectively. Calp (calpeptin); rhoA activator (0.5 mU/mL). p<0.05 in all cases as determined by one-way ANOVA followed by Tukey test.

    Article Snippet: Calpeptin (Calp, 400 mU/µL, DMF) and the cell permeable rhoA inhibitor (C3 transferase, 1 mg/mL, H 2 O) were purchased from Cytoskeleton, Inc (Denver, CO, USA).

    Techniques: Activity Assay

    Panels A-D correspond to WB data derived using an Ab directed toward the C-terminus of RLC. A. Representative WBs demonstrating RLC phospho-states separated by Mn 2+ -phos-tag SDS-PAGE. Uterine myocytes were lysed and total protein was harvested after the following treatments: untreated, or treated with g-H, Calp, OT, or with their corresponding vehicles. B. Quantification of bands identified in panel A (untreated; n = 12, g-H; n = 5, Calp; n = 8, OT; n = 7). The signals derived from 0pRLC T , 1pRLC T , and 2pRLC T are expressed as the proportion of their sum total within each lane. C. Absolute magnitude of the difference in each phospho-state caused by the treatments in comparison to the corresponding vehicle (‘+’ indicates enhancement relative to vehicle, ‘−’ indicates diminution relative to vehicle). D. Vehicle-corrected distribution data obtained by combining the data in panel C to the untreated group distribution. g-H (glycyl-H-1152); ROK inhibitor (1 µM). Calp (calpeptin); rhoA activator (0.5 mU/mL). OT; oxytocin (100 nM). All data are shown as means ± SEMs. The corresponding numerical data are compiled in .

    Journal: PLoS ONE

    Article Title: Phos-Tag-Based Analysis of Myosin Regulatory Light Chain Phosphorylation in Human Uterine Myocytes

    doi: 10.1371/journal.pone.0020903

    Figure Lengend Snippet: Panels A-D correspond to WB data derived using an Ab directed toward the C-terminus of RLC. A. Representative WBs demonstrating RLC phospho-states separated by Mn 2+ -phos-tag SDS-PAGE. Uterine myocytes were lysed and total protein was harvested after the following treatments: untreated, or treated with g-H, Calp, OT, or with their corresponding vehicles. B. Quantification of bands identified in panel A (untreated; n = 12, g-H; n = 5, Calp; n = 8, OT; n = 7). The signals derived from 0pRLC T , 1pRLC T , and 2pRLC T are expressed as the proportion of their sum total within each lane. C. Absolute magnitude of the difference in each phospho-state caused by the treatments in comparison to the corresponding vehicle (‘+’ indicates enhancement relative to vehicle, ‘−’ indicates diminution relative to vehicle). D. Vehicle-corrected distribution data obtained by combining the data in panel C to the untreated group distribution. g-H (glycyl-H-1152); ROK inhibitor (1 µM). Calp (calpeptin); rhoA activator (0.5 mU/mL). OT; oxytocin (100 nM). All data are shown as means ± SEMs. The corresponding numerical data are compiled in .

    Article Snippet: Calpeptin (Calp, 400 mU/µL, DMF) and the cell permeable rhoA inhibitor (C3 transferase, 1 mg/mL, H 2 O) were purchased from Cytoskeleton, Inc (Denver, CO, USA).

    Techniques: Derivative Assay, SDS Page